Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × OTHER × 177Lu-octreotate × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cisplatin 251 Radiotherapy 208 Fluorouracil 182 Cyclophosphamide 171 Capecitabine 168 Oxaliplatin 149 Docetaxel 148 Gemcitabine 139 Paclitaxel 133 Carboplatin 133 Dexamethasone 111 Leucovorin 110 Drug Therapy 104 Doxorubicin 103 Etoposide 87 Bevacizumab 79 Vincristine 77 Cytarabine 77 Irinotecan 73 Rituximab 69 Epirubicin 64 Prednisone 60 Methotrexate 56 Radiosurgery 53 Radiation 53 Surgical Procedures, Operative 51 Radiotherapy, Intensity-Modulated 50 Lenalidomide 49 Neoadjuvant Therapy 48 Letrozole 46

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡